KUALA LUMPUR, May 25 (Bernama) -- Clinigen Group plc, a global pharmaceutical and services company has signed an agreement with Nordic Pharma Ltd to supply and distribute aprotinin in a range of countries in Asia Pacific and South Africa including Malaysia.
Under the terms of this agreement, Clinigen will make aprotinin available to physicians and pharmacists on an unlicensed, on-demand basis for patients who lack other suitable therapeutic options in a number of countries.
The agreement grants Clinigen the exclusive rights to supply aprotinin in Australia, New Zealand, Japan, Singapore, Malaysia, Taiwan, Thailand, Hong Kong and South Africa, a statement said.
"This agreement demonstrates Clinigen's ongoing commitment to providing physicians and pharmacists with the access to medicines they require to address patients' unmet medical needs," said head of Global Access at Clinigen, Julie Gosper in a statement.
"Nordic Pharma is committed to improving the access to aprotinin worldwide, which is an important lifesaving product in the arsenal of patient blood management," said chief executive officer of Nordic Pharma, Hans Schram.
Aprotinin Injection belongs to a group of medicines called anti-fibrinolytics (medicines to prevent blood loss). It can help to reduce blood loss and the need for blood transfusions during isolated cardiopulmonary bypass graft surgery.
Healthcare professionals can obtain details about aprotinin by emailing medicineaccess@clinigengroup.com.
No comments:
Post a Comment